New ultrasound could predict chemo success in weeks, not months

NCT ID NCT07583381

Not yet recruiting Diagnosis Sponsor: The First Hospital of Jilin University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a special ultrasound technique called contrast-enhanced subharmonic ultrasound to see if it can predict whether chemotherapy is working for colorectal cancer that has spread to the liver. Currently, doctors wait about 2 months for CT or MRI scans to see if tumors shrink. This ultrasound looks at blood flow inside tumors after just 1-2 chemo cycles. The trial will enroll 107 adults with newly diagnosed liver metastases who haven't had treatment yet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: contrast-enhanced subharmonic ultrasound
What this could lead to: If successful, this ultrasound technique could help doctors quickly tell if chemotherapy is working for liver tumors, allowing faster treatment adjustments.
What could go wrong: This is an early-stage diagnostic study with only 107 participants, so results may not apply to everyone. The technology may not reliably predict treatment response in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL LIVER METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal neoplasm liver and intrahepatic bile duct neoplasm Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL LIVER METASTASIS COLORECTAL NEOPLASMS LIVER NEOPLASMS

More trials for these conditions

Other studies related to the condition(s) this trial covers.